These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 10325362

  • 1. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
    Jones RN, Biedenbach DJ, Erwin ME, Beach ML, Pfaller MA.
    J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
    [Abstract] [Full Text] [Related]

  • 2. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ, Jones RN, Pfaller MA, Sentry Participants Group (Americas and Europe).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [Abstract] [Full Text] [Related]

  • 3. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
    Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):91-8. PubMed ID: 10354857
    [Abstract] [Full Text] [Related]

  • 4. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
    Bell JM, Turnidge JD, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
    [Abstract] [Full Text] [Related]

  • 5. Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
    Anderegg TR, Biedenbach DJ, Jones RN, Quality Control Working Group.
    Diagn Microbiol Infect Dis; 2003 Jun; 46(2):147-50. PubMed ID: 12812719
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
    Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ, CROSS Study Group.
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1875-81. PubMed ID: 12760861
    [Abstract] [Full Text] [Related]

  • 7. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [Abstract] [Full Text] [Related]

  • 8. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN, SENTRY Study Group (Latin America).
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [Abstract] [Full Text] [Related]

  • 9. In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Flamm RK, Rhomberg PR, Huband MD, Farrell DJ.
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6381-5. PubMed ID: 27458220
    [Abstract] [Full Text] [Related]

  • 10. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.
    Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF.
    Clin Microbiol Infect; 2003 Jul; 9(7):590-9. PubMed ID: 12925097
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Brueggemann AB, Kugler KC, Doern GV.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.
    Cormican MG, Erwin ME, Marshall SA, Jones RN.
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):155-60. PubMed ID: 8724401
    [Abstract] [Full Text] [Related]

  • 13. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
    Jones RN, Kugler KC, Erwin ME, Biedenbach DJ, Beach ML, Pfaller MA.
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):247-53. PubMed ID: 10212751
    [Abstract] [Full Text] [Related]

  • 14. Disk diffusion versus broth microdilution susceptibility testing of Haemophilus species and Moraxella catarrhalis using seven oral antimicrobial agents: application of updated susceptibility guidelines of the National Committee for Clinical Laboratory Standards.
    Kibsey PC, Rennie RP, Rushton JE.
    J Clin Microbiol; 1994 Nov; 32(11):2786-90. PubMed ID: 7852573
    [Abstract] [Full Text] [Related]

  • 15. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
    Gales A, Sader H, Jones RN, SENTRY Participants Group (Latin America).
    Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
    [Abstract] [Full Text] [Related]

  • 16. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
    Kitzis MD, Goldstein FW, Miegi M, Acar JF.
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
    [Abstract] [Full Text] [Related]

  • 17. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 18. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 19. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Apr; 36(4):255-9. PubMed ID: 10764968
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.
    Biedenbach DJ, Croco MA, Barrett TJ, Jones RN.
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):428-31. PubMed ID: 10442421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.